Double-negative Feedback Loop Between ZEB2 and MiR-145 Regulates Epithelial-mesenchymal Transition and Stem Cell Properties in Prostate Cancer Cells
Overview
Cell Biology
Authors
Affiliations
The invasion and metastasis of tumors are triggered by an epithelial to mesenchymal transition (EMT), which is regulated by microRNAs (miRNAs). EMT also promotes malignant tumor progression and the maintenance of the stem cell property, which endows cancer cells with the capabilities of self-renewal and immortalized proliferation. The transcriptional repressor zinc-finger E-box binding homeobox 2 (ZEB2), as an EMT activator, might be an important promoter of metastasis in some tumors. Here, we report that ZEB2 directly represses the transcription of miR-145, which is a strong repressor of EMT. In turn, ZEB2 is also a direct target of miR-145. Further, our findings show that the downregulation of ZEB2 not only represses invasion, migration, EMT, and the stemness of prostate cancer (PCa) cells, but also suppresses the capability of PC-3 cells to invade bone in vivo. Importantly, the expression level of ZEB2 as revealed by immunohistochemical analysis is positively correlated to bone metastasis, the serum free PSA level, the total PSA level, and the Gleason score in PCa patients and is negatively correlated with miR-145 expression in primary PCa specimens. Thus, our findings demonstrate a double-negative feedback loop between ZEB2 and miR-145 and indicate that the ZEB2/miR-145 double-negative feedback loop plays a significant role in the control of EMT and stem cell properties during the bone metastasis of PCa cells. These results suggest that the double-negative feedback loop between ZEB2 and miR-145 contributes to PCa progression and metastasis and might have therapeutic relevance for the bone metastasis of PCa.
Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy.
Liang H, Zhou B, Li P, Zhang X, Zhang S, Zhang Y Ann Med. 2024; 57(1):2442067.
PMID: 39711287 PMC: 11703425. DOI: 10.1080/07853890.2024.2442067.
MicroRNA in prostate cancer: from biogenesis to applicative potential.
Luo X, Wen W BMC Urol. 2024; 24(1):244.
PMID: 39506720 PMC: 11539483. DOI: 10.1186/s12894-024-01634-1.
Xie D, Li Z, Ren B, Gong R, Yang D, Huang S Chin J Integr Med. 2024; .
PMID: 39499413 DOI: 10.1007/s11655-024-4118-5.
Recent progress in microRNA research for prostate cancer.
Yuan F, Hu Y, Lei Y, Jin L Discov Oncol. 2024; 15(1):480.
PMID: 39331237 PMC: 11436510. DOI: 10.1007/s12672-024-01376-4.
Armstrong L, Willoughby C, McKenna D Int J Mol Sci. 2024; 25(8).
PMID: 38673886 PMC: 11050364. DOI: 10.3390/ijms25084301.